

Supplementary Materials for

Imaging CAR T cell therapy with PSMA-targeted positron emission tomography

Il Minn, David J. Huss, Hye-Hyun Ahn, Tamara M. Chinn, Andrew Park, Jon Jones, Mary Brummet, Steven P. Rowe, Polina Sysa-Shah, Yong Du, Hyam I. Levitsky, Martin G. Pomper*

*Corresponding author. Email: mpomper@jhmi.edu

Published 3 July 2019, *Sci. Adv.* **5**, eaaw5096 (2019)
DOI: 10.1126/sciadv.aaw5096

This PDF file includes:

Fig. S1. DCFPyL does not affect CD19-tPSMA^(N9del) CAR T cells in vitro.




Fig. S1. DCFPyL does not affect CD19-tPSMA^(N9del) CAR T cells in vitro.

CD19-tPSMA^(N9del) CAR-T cells were incubated with increasing concentrations of DCFPyL. (A) A kill index was calculated; (B) IFN γ production at 24 h post-activation on K562-CD19 target cells. Data are representative of two independent experiments with two independent donors.

Abbreviations

CAR: chimeric antigen receptor

PET: positron emission tomography

SPECT: single photon emission computed tomography

MR: magnetic resonance

HSV1-TK: herpes simplex virus type 1 thymidine kinase

fLuc: firefly luciferase

SSTR2: type 2 somatostatin receptor

[⁶⁸Ga]DOTATATE: ⁶⁸Ga-DOTA-DPhe1, Tyr3-octreotate

[¹⁸F]DCFPyL: 2-(3-{carboxy-5-[(6-[(¹⁸F]fluoro-pyridine-3-carbonyl)-amino]-pentyl]-ureido)-pentanedioic acid